Argenx Shares Drop 2.78% Amid 58.83% Volume Surge Ranks 378th in Daily Trading as Q4 Earnings Loom

Market Snapshot

argenx (ARGX) closed on February 25, 2026, with a 2.78% decline in share price, marking a negative day for the biotechnology stock. Despite the drop, trading volume surged by 58.83% to $360 million, ranking the stock 378th in daily volume activity. The elevated volume suggests heightened investor interest, potentially driven by anticipation of the company’s Q4 2025 earnings release scheduled for February 26. However, the price decline indicates mixed sentiment, with market participants possibly factoring in near-term risks or reassessing valuation metrics ahead of the earnings report.

Key Drivers

The upcoming Q4 2025 earnings release on February 26 is a critical catalyst for argenx’s near-term trajectory. Analysts project revenue of $1.1 billion and earnings per share (EPS) of $5.11–$6.24, reflecting a 76% year-over-year revenue growth. These expectations contrast with the company’s previous quarter, where actual results outperformed estimates (revenue: $976.55 million vs. $895.62 million; EPS: $4.39 vs. $3.65). Despite beating expectations in September 2025, the stock fell 1.98% post-announcement, signaling that strong results may not always translate to immediate price gains. This historical pattern could amplify volatility ahead of the Q4 report, particularly as analysts and institutional investors closely monitor whether the company can sustain its growth momentum.

Analyst sentiment remains cautiously optimistic, with price targets and brokerage recommendations underscoring long-term potential. The average 12-month target from 16 analysts is $860.51, implying a 21% upside from the current price of $709.20. However, GuruFocus’ estimated intrinsic value ($1,589.50) is nearly double the average target, suggesting a significant disparity in valuation expectations. Brokerage recommendations also lean bullish, with an average score of 1.8 (on a 1–5 scale), indicating an “Outperform” rating. This divergence highlights a key debate: while the market acknowledges argenx’s innovation in FcRn-targeting therapies like Vyvgart, skepticism persists about its ability to scale profitably and maintain margins amid regulatory and competitive pressures.

Institutional investor activity further complicates the outlook. Optiver Holding B.V. reduced its stake by 34.9% in Q3 2025, trimming 6,066 shares to 11,328, while other firms like Bessemer Group and MAI Capital Management increased holdings by 276.5% and 866.7%, respectively. This mixed activity reflects both caution and conviction. The 60.32% institutional ownership stake underscores the stock’s appeal to professional investors, but recent trimming suggests some hedging against potential earnings misses or sector-wide volatility. Notably, the stock’s 31.96% gain over the past 52 weeks has attracted momentum-driven investors, yet its 0.83% one-month loss hints at short-term profit-taking.

Estimate trends for 2025 and 2026 reveal a nuanced picture of growth expectations. Revenue estimates for 2025 rose marginally from $3.57 billion to $3.58 billion, while 2026 projections climbed from $4.87 billion to $4.96 billion. Earnings estimates, however, show a decline in 2025 (from $14.97 to $14.79 per share) but a rebound in 2026 (from $23.98 to $25.15 per share). This suggests analysts expect near-term profit compression but confidence in long-term margin expansion. The divergence between revenue and earnings trajectories could be attributed to rising R&D costs or pricing pressures in the biotech sector. Additionally, the stock’s price-to-earnings ratio of 36.08 and PEG ratio of 0.71 indicate it is trading at a premium relative to earnings growth, raising questions about whether the valuation is fully justified by fundamentals.

The market’s reaction to argenx’s recent performance highlights a tension between short-term volatility and long-term potential. While the 2.78% price drop on February 25 contrasts with the stock’s 34.51% annual gain, the surge in trading volume suggests that investors are actively reassessing risk-reward dynamics. This could be driven by factors such as the FDA’s priority review of Vyvgart’s label expansion, CEO transition announcements, or broader sector trends in biotech. The stock’s 52-week range ($510.05–$934.62) also underscores its inherent volatility, with momentum traders likely capitalizing on swings between its moving averages ($830.51 for 50 days and $810.08 for 200 days). As the Q4 earnings report approaches, the interplay of these factors will likely determine whether the current correction is a buying opportunity or a cautionary signal.